Wall Street brokerages predict that Vaxart, Inc. (NASDAQ:VXRT – Get Rating) will report ($0.20) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Vaxart’s earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.22). Vaxart posted earnings per share […]
A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase 1 data measuring cross-reactivity also included in.
Vaxart (NASDAQ:VXRT – Get Rating) and Relay Therapeutics (NASDAQ:RLAY – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings. Volatility and Risk Vaxart has a beta of 0.41, indicating that […]
Vaxart (NASDAQ:VXRT – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The […]